Antisense oligonucleotides as therapeutic agents

Pharmacological Research

Volumn 36, Issue 3, 1997, Pages 171-178

  Alama, Angela ^a   Barbieri, Federica ^a   Cagnoli, Monica ^a   Schettini, Gennaro ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antisense oligonucleotides; Gene expression; Oncogenes; Viral targets

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; DRUG CARRIER; FOMIVIRSEN; MESSENGER RNA; TRECOVIRSEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHMA; CLINICAL TRIAL; DNA RNA HYBRIDIZATION; DRUG DEGRADATION; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC DISORDER; HUMAN; INFLAMMATORY DISEASE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MELANOMA; MEMBRANE TRANSPORT; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; ONCOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RIBOSOME; RNA CLEAVAGE; RNA TRANSLATION; VIROLOGY; VIRUS INFECTION;

EID: 0031234479     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0227     Document Type: Article

References (53)

1. 1. Walker I, Irwin WJ, Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 1995; 12: 1548-53.
2. 2. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate polyethyleneglycol. Proc Natl Acad Sci USA 1995; 92: 3318-22.
3. 3. Lewis JG, Lin KY, Kothvale A, Flanagan WM, Matteucci MD, Deprince RB, Mook RA Jr, Hendren RW, Wagner RW. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 1996; 93: 3176-81.
4. 4. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumour dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-16.
5. 5. Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des 1991; 6: 531-8.
6. 6. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R. Adsorption, tissue distribution and in vivo stability in rats of an hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 1995; 50: 571-6.
7. 7. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 1995; 49: 929-39.
8. 8. Zhang R, Yan J, Shahinian H, Hamin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB. Pharmacokinetics of an anti-HIV antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 1995; 58: 44-53.
9. 9. Bishop MR, Iversen PL, Bayever RE, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense OL (1) p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6.
10. 10. Gao WY, Han FS, Storm C, Egan W, Cheng YC. Phosporothioate oligonucleotides are inhibitors of human DNA polymerases and RNAse H: implications for antisense technology. Mol Pharmacol 1992; 41: 223-9.
11. 11. Maury G, Abdelaziz E, Morvan F, Muller B, Imbach J, Goody RS. Template, phosphorothioate oligonucleotides duplexes as inhibitors of HIV-1 reverse transciptase. Biochem Biophys Res Commun 1992; 186: 1249-56.
12. 12. Sharma HW, Hsiao R, Narayanan R. Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Res Dev 1996; 6: 3-7.
13. 13. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L. Aptamericinhibition of p210 bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotide of defined sequence and backbone structure. Nucleic Acids Res 1994; 22: 2150-4.
14. 14. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-I. Biochem Pharmacol 1993; 45: 2037-43.
15. 15. McIntyre KW, Lombard-Gilloly K, Perez JR, Sarmiento UM, Larigan JD, MLandreth KT, Narayanan R. A sense phosphorothioate oligonudeotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation. Antisense Res Dev 1993; 3: 309-22.
16. 16. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991; 56: 1-48.
17. 17. Wickstrom EL, Bacon TA, Gonzales A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukaemia HL-60 cell proliferation and c-myc protein expressing are inhibited by antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 1988; 85: 1028-32.
18. 18. Holt JR, Redner RL, Nienhuis AW. An oligomercomplementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cell and induces differentiation. Mol Cell Biol 1988; 8: 963-73.
19. 19. Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Ferrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxyoligonucleotide in human T lymphocytes. J Immunol 1988; 140: 1427-48.
20. 20. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguernera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibiton of leukaemic cell proliferation by bcr/abl antisense oligodeoxynucleotides. Science 1991; 253: 562-5.
21. 21. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, lozzo RV, Zon G, Calabretta B. Suppression of Philadelphia leukaemia cell growth in mice by bcr/abl antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 91: 4504-8.
22. 22. Skorski T, Nieborowska-Skorska M, Wlodarrski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christense L, lozzo RV, Calabretta B. Treatment of Philadelphia leukaemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997; 89: 124-32.
23. 23. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-20.
24. 24. Reed JC, Cuddy M, Halder S, Croce C, Nowell P. Bcl-2 mediated tumourigenicity of a human T-lymphoid cell line: synergy with myc and inhibition by bcl-2 antisense. Proc Natl Acad Sci USA 1990; 87: 3660-4.
25. 25. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdam M, Al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995; 2: 207-12.
26. 26. Pocock C, Al-Mahdi N, Hall P, Morgan G, Cotter F. In vivo suppression of B-cell lymphoma with bcl-2 antisense oligonucleotides. Blood 1993; 92 (suppl): 200a.
27. 27. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71: 429-37.
28. 28. Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE. p53 gene mutation analysis and antisense mediated growth inhibition of human ovarian cercinomacell lines. Gynecol Oncol 1996; 60: 72-80.
29. 29. Hirota Y, Horiuchi T, Akahane K. p53 antisense oligonucleotide inhibits growth of human colon tumour and normal cell lines. Jpn J Cancer Res 1996; 87: 735-42.
30. 30. Szczylik C, Skorski T, Malaguarnera L, Hetman J, Chen ST, Calabretta B. Inhibition of in vitro proliferation of chronic myalogenous leukaemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem Cytobiol 1996; 434: 129-34.
31. 31. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM. Biologic and therapeutic significance of myb expression in human melanoma. Proc Natl Acad Sci USA 1994; 921: 4499-503.
32. 32. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta, Citro G, Zupi G. Antitumour effect of c-myc antisense phosphothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996; 88: 419-29.
33. 33. Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M, Averette HE. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol 1997; 64: 18-25.
34. 34. Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Stein CA, Mitsuya H, Wong-Staal F, Cohen J, Broder S. Regulation of viral expression of HIV (Human Immunodeficiency Virus) in vitro by antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad USA 1989; 86: 4244-9.
35. 35. Lisziewicz J, Sun D, Metelev V, Zamecnik P, Gallo RC, Agrawal S. Long term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA 1993; 90: 3860-4.
36. 36. Weichold FF, Lisziewicz J, Zeman RA, Nerurkar LS, Agrawal S, Reitz MS, Gallo RC. Antisense phosphotothioate oligodeoxynucleotides alter HIV type 1 replication in human cultured human macrophages and peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1995; 11: 863-7.
37. 37. Akhtar S, Rossi JJ. Anti-HIV therapy with antisense oligonucleotides and rybozimes: realistic approaches or expensive myths? J Antimicrob Chemother 1996; 38: 159-65.
38. 38. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997; 107: 41-4.
39. 39. Azad RF, Brown-Driver V, Buckeit RW, Anderson KP. Antiviral activity of phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus when used in combination with antiviral nucleoside analogs. Antiviral Res 1995; 28: 101-11.
40. 40. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996; 40: 2004-11.
41. 41. Palestine AG, Cantrill HL, Luckie AP, Ai E. Intravitreal treatment of CMV retinitis with an antisense oligonucleotide, ISIS 2922. Presented at the 10th International Conference on AIDS, Yokohama, Japan. August 1-12, 1994 (abstract).
42. 42. Cohen J. New hope against blindness. Science 1995; 268: 3568-9.
43. 43. Moriya K, Matsukura M, Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphotothioate oligonucleotides. Biochem Biophys Res Commun 1996; 218: 217-23.
44. 44. Vidalin O, Major ME, Rayner B, Imbach JL, Trepo C, Inchauspè G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob Agents Chemother 1996; 40: 2337-44.
45. 45. Shoji Y, Shimada J, Mizushima Y, Iwasawa A, Nakamura Y, Inouye I, Azuma T, Sakurai M, Nishimura T. Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. Antimicrob Agents Chemother 1996; 40: 1670-5.
46. 46. Henry SP, Grillone LR, Orr JL, Bruner RH, Kornbrust DJ. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides following subacute intradermal administration in Sprague-Dawley rats. Toxicology 1997; 116: 77-88.
47. 47. Sierakowska H, Sambade MJ, Agrawal S, Kole TR. Repair of thalassemic beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 1996; 93: 12840-4.
48. 48. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 285: 721-5.
49. 49. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1997; 2: 998-1004.
50. 50. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosemberg RD. Antisense c-myb oligonucleotides inhibit initial arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
51. 51. Biro S, Fu YM, Yu ZX, Epstein SE. inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 1993; 890: 654-5658.
52. 52. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular of smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-8.
53. 53. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-87.